VCEL vs. DNLI, KYMR, CGON, BEAM, DNA, TWST, FUSN, RXRX, SANA, and NMRA
Should you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Denali Therapeutics (DNLI), Kymera Therapeutics (KYMR), CG Oncology (CGON), Beam Therapeutics (BEAM), Ginkgo Bioworks (DNA), Twist Bioscience (TWST), Fusion Pharmaceuticals (FUSN), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA), and Neumora Therapeutics (NMRA). These companies are all part of the "biological products, except diagnostic" industry.
Vericel (NASDAQ:VCEL) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.
Vericel has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.
In the previous week, Vericel had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Vericel and 3 mentions for Denali Therapeutics. Vericel's average media sentiment score of 0.92 beat Denali Therapeutics' score of 0.04 indicating that Vericel is being referred to more favorably in the media.
Denali Therapeutics received 103 more outperform votes than Vericel when rated by MarketBeat users. Likewise, 67.38% of users gave Denali Therapeutics an outperform vote while only 62.38% of users gave Vericel an outperform vote.
92.9% of Denali Therapeutics shares are owned by institutional investors. 7.2% of Vericel shares are owned by company insiders. Comparatively, 7.9% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Vericel currently has a consensus target price of $46.40, suggesting a potential downside of 0.41%. Denali Therapeutics has a consensus target price of $41.22, suggesting a potential upside of 161.56%. Given Denali Therapeutics' higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than Vericel.
Vericel has a net margin of -1.61% compared to Denali Therapeutics' net margin of -36.51%. Vericel's return on equity of -1.55% beat Denali Therapeutics' return on equity.
Vericel has higher earnings, but lower revenue than Denali Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Vericel beats Denali Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Vericel News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
